Impact of invasive bladder cancer and orthotopic urinary diversion on general health-related quality of life: An SF-36 survey

Similar documents
Eiji Kikuchi, Yutaka Horiguchi, Jun Nakashima, Takashi Ohigashi, Mototsugu Oya, Ken Nakagawa, Akira Miyajima and Masaru Murai

Point/Counterpoint: Quality of Life Considerations for Patients with Muscle Invasive Bladder Cancer Pro Trimodality Therapy

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

When to Integrate Surgery for Metatstatic Urothelial Cancers

Ileal orthotopic neo-bladder (IOB): how Quality of Life (QoL) of recipients can be measured. M.Niero (Dept of Education University of Verona ITA)

Optimal Timing of Radical Cystectomy for Patients with Invasive Transitional Cell Carcinoma of the Bladder

Predictors of use of orthotopic bladder reconstruction after radical cystectomy for bladder cancer: Data from a pilot study of 2414 cases

Quality of life after radical cystectomy for bladder cancer in men with an ileal conduit or continent urinary diversion: A comparative study

Radical cystectomy for bladder cancer: oncologic outcome in 271 Chinese patients

The outcome of non-muscle invasive urinary bladder tumour at Makassed General Hospital

Radical Cystectomy Often Too Late? Yes, But...

Cystectomies and bladder preservation: What you need to know

URINARY DIVERSIONS. Winter 2016 Dr P. O Malley

Trimodality Therapy for Muscle Invasive Bladder Cancer

Clinical Commissioning Policy Proposition: Robotic Assisted Surgery for Bladder Cancer

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto

Bladder replacement in men and women: when and when not? Outline. Continent Diversion History

Body Image Following Radical Cystectomy and Ileal Neobladder or Conduit in Korean Patients

Bladder Sparing Treatment of Muscle Invasive Bladder Cancer

Huang et al. BMC Urology (2015) 15:117 DOI /s

MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

ROBOTIC VS OPEN RADICAL CYSTECTOMY

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series

Introduction. Teck Wei Tan 1,2 Rajesh Nair 1 Sanad Saad 1 Ramesh Thurairaja 1 Muhammad Shamim Khan 1

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016

Dr. Tareq Salah Ahmed,MD,ESMO. Lecturer of clinical oncology, Assiut faculty of medicine ESMO accreditation certificate

Microscopic Study of Histological Changes the Use of Ileal Mucosa as a Bladder (Radical Cystectomy - Case Report)

The quality of life in men after radical cystectomy with a continent cutaneous diversion or orthotopic bladder substitution: is there a difference?

Long-Term Complications of Conduit Urinary Diversion

Sexuality Preserving Cystectomy and Neobladder (SPCN): Functional Results of a Neobladder Anastomosed to the Prostate

Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy

Bladder Preservation Strategies for Muscle Invasive Bladder Cancer

International Journal of Health Sciences and Research ISSN:

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

Part II: Treatment. A Woman-to-Woman Talk with Dr. Armine Smith. Wednesday, March 8, Presented by

Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer

Multiple Primary and Histology Site Specific Coding Rules URINARY. FLORIDA CANCER DATA SYSTEM MPH Urinary Site Specific Coding Rules

Oral Communications & Posters

10th anniversary of 1st validated CaPspecific

CHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre

AUA Guidelines for Invasive Bladder Cancer: What s New?

Citation International journal of urology (2. Right which has been published in final f

Organ-sparing treatment of invasive transitional cell bladder carcinoma

Standardized analysis of complications after robot-assisted radical cystectomy: Korea University Hospital experience

MEDitorial March Bladder Cancer

Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors

Clinical Value of C-reactive Protein and Erythrocyte Sedimentation Rate in Advanced Bladder Cancer

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer

Risk of in-hospital complications after radical cystectomy for urinary bladder carcinoma: population-based follow-up study of 7608 patients

2014 Best Papers in Robotic Cystectomy

Urological Tumours 1 Kidney tumours 2 Bladder tumours

Running head: Treatment modality and long term renal function in MIBC-Hamidi et al.

Recovery of sexual function after radical cystectomy with orthotopic neobladder

Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital

Controversies in the management of Non-muscle invasive bladder cancer

Chemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008

Muscle-invasive bladder cancer

Partial Cystectomy for Invasive Bladder Cancer

The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma

Efficacy of Bladder-Preserving Therapy for Patients with T3b, T4a, and T4b Transitional Cell Carcinoma of the Bladder

REVIEW. Patterns of recurrence of bladder carcinoma following radical cystectomy

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

Medication is injected into your bladder to encourage your immune system to attack and destroy the cancer cells.

Technique of transurethral needle core biopsy to confirm invasive bladder cancer staging

Collection of Recorded Radiotherapy Seminars

Bladder Cancer Basics For the Newly Diagnosed

URINARY DIVERSIONS. Susan Hilton, MD and Nicholas Papanicolaou, MD Co-Chiefs, CT Section Hospital of the University of Pennsylvania

Anterior urethra sparing cystoprostatectomy for bladder cancer: a 10 year, single center experience

A rare case of adenocarcinoma of bl augmentation enterocystoplasty. Citation 泌尿器科紀要 (1985), 31(2):

UNDERSTANDING BLADDER CANCER

Attachment #2 Overview of Follow-up

Curie - davinci connection

Radical Cystectomy for Urothelial Carcinoma of the Bladder Without Neoadjuvant or Adjuvant Therapy: Long-Term Results in 1100 Patients

Effect of internal iliac artery chemotherapy after transurethral resection of bladder tumor for muscle invasive bladder cancer

Prostate artery embolization (PAE) for benign prostatic enlargement (BPE) 1

A Design of Efficient Medical Information System to Enhance Health Behaviors after Radical Prostatectomy

EAU MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER

Urethral Carcinoma Recurrence in Ileal Orthotopic Neobladder: Urethrectomy and Conversion in a Continent Pouch with Abdominal Stoma

Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma

Minimal Invasive Approach ro radical cystectomy: Results of the European multicentric study

Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC

The Motion: Perioperative Chemotherapy in Muscle Invasive Bladder Cancer Improves Survival

UROTHELIAL CELL CANCER

90% of bladder tumours are transitional cell carcinoma (TCC), the remaining 10% of cases are squamous cell carcinoma, adenocarcinoma and sarcoma.

A comparison of preliminary oncologic outcome and postoperative complications between patients undergoing either open or robotic radical cystectomy

TCC recurrence within the upper tract urothelium following

Chemotherapy Treatment Algorithms for Urology Cancer

Research Article Urinary Catheterization May Not Adversely Impact Quality of Life in Multiple Sclerosis Patients

The Association Between The Prognosis Of Ureteral Cancer And Natural Constriction By The Common Iliac Arteriovenous Crossing

Prognostic features for quality of life after radical cystectomy and orthotopic neobladder

Wednesday 21st September - Leeds

Bricker versus Wallace anastomosis: A meta-analysis of ureteroenteric stricture rates after ileal conduit urinary diversion

Hematuria Awareness for Patients

Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.

Alexandra Savova, Guenka Petrova. Medical University Sofia Faculty of Pharmacy

Index. Note: Page numbers of article titles are in boldface type.

Transcription:

758 Impact of invasive bladder cancer and orthotopic urinary diversion on general health-related quality of life: An SF-36 survey MINGYING YANG 1,2*, HAIFENG WANG 2*, JIANSONG WANG 2 and MINGHUI RUAN 1 Departments of 1 Nursing and 2 Urology, The Second Affiliated Hospital of Kunming Medical University, Yunnan Institute of Urology, Kunming, Yunnan 650101, P.R. China Received November 26, 2012; Accepted April 9, 2013 DOI: 10.3892/mco.2013.125 Abstract. Bladder cancer is a common type of genitourinary cancer, and radical cystectomy with urinary diversion is considered to be the most effective local treatment for invasive bladder cancer. In order to assess the functional results and health-related quality of life (QOL) in bladder cancer patients with an orthotopic neobladder, and to provide a reasonable basis for the evaluation of urinary diversion in situ, we conducted a study on 96 neobladder patients. In December, 2011, questionnaires were mailed to 96 patients that had undergone urinary diversion surgery between January, 2007 and December, 2009. The questionnaire included the validated health-related QOL questionnaire and the MOS 36-item Short Form Health Survey (SF-36). We compared the functional results between patients with an orthotopic neobladder and those with other types of urinary diversion at 6, 12 and 24 months after surgery. Data from 82 patients (54 with orthotopic and 28 with non orthotopic urinary diversion) were included in the analysis. The SF-36 patient scores following orthotopic urinary diversion were significantly higher than those following non-orthotopic urinary diversion. The majority of patients with orthotopic urinary diversion considered themselves as healthy and their scores of total health were higher compared to those of patients with non-orthotopic urinary diversion. However, there were no differences in the scores of physical functioning between patients with orthotopic and those with non-orthotopic urinary diversion. Our findings regarding health-related QOL and the frequency of complications in the orthotopic and the non orthotopic urinary diversion groups were similar. However, the mental health of patients Correspondence to: Professor Jiansong Wang, Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Yunnan Institute of Urology, Kunming, Yunnan 650101, P.R. China E-mail: jiansongwang@126.com * Contributed equally Key words: bladder neoplasms, orthotopic, urinary diversion, quality of life, SF-36 general health survey with orthotopic urinary diversion was more easily restored compared to that of patients with non orthotopic urinary diversion, which reduced their overall recovery time. Introduction Bladder cancer is a common type of genitourinary cancer. Radical cystectomy with urinary diversion is considered to be the most effective local treatment for invasive bladder cancer (1,2). As regards quality of life (QOL), including urinary, sexual and social functioning, daily living activities and body image satisfaction, orthotopic continent diversions are considered the gold standard among reconstructive procedures (3-5). However, QOL has not been sufficiently assessed in non-metastatic bladder cancer patients (NMBC) (6). Therefore, available data on the comparison of the impact of different treatments on the QOL of NMBC patients are limited (7). The MOS 36-item Short Form Health Survey (SF-36) score is extensively used worldwide and is considered to be accurate (8-11). SF-36 has become a standard questionnaire and it may be applied to patients as well as to healthy subjects. In addition, the questions may be easily answered within a short time and they are limited to the evaluation of basic issues regarding overall health. In this study, we compared the functional results between patients with an orthotopic and those with a non-orthotopic neobladder at 6, 12 and 24 months after surgery, using the SF-36 method. Patients and methods Patients. Between January, 2007 and December, 2009, an orthotopic neobladder reconstruction was performed on 54 patients (experimental group). In addition, non-orthotopic neobladder surgery (cutaneous diversion), was performed in 28 patients (control group). The experimental group included 50 patients with transitional cell carcinoma (5 with T1, 31 with T2 and 14 with T3), 2 with squamous cell carcinoma, 1 with adenocarcinoma and 1 with neuroendocrine carcinoma (mean age of the 54 patients, 66.0 years). The control group included a total of 28 patients with a non-orthotopic neobladder, 27 of which had transitional cell carcinoma (14 had T2, 12 had T3 and 1 had T4) and 1 had adenocarcinoma (T2) (mean age of the 28 patients, 65.6 years). The 82 patient samples were all confirmed by pathological examination following surgery. This study complies with current ethical considerations. The

YANG et al: GENERAL HEALTH SURVEY ON ORTHOTOPIC URINARY DIVERSION SURGERY 759 Table I. Comparison of data from the Short Form Health Survey (SF-36) between the experimental and control groups at 6 months. Items Experimental group (n=54) Control group (n=28) P-value Physical functioning 22.13±5.42 21.26±3.04 0.27 Role-physical functioning 6.32±1.04 5.34±0.74 0.08 Bodily pain 8.36±1.41 7.52±2.63 0.29 General health 14.82±3.19 12.26±4.27 0.14 Vitality 15.49±2.88 16.62±5.43 0.31 Social functioning 7.83±1.15 4.49±1.29 0.01 Role-emotional functioning 3.96±1.03 3.73±0.82 0.77 Mental health 21.49±3.37 16.20±4.33 0.02 Overall health 105.80±18.49 96.36±16.42 0.11 Total physical health 52.23±7.74 49.76±6.20 0.32 Total mental health 51.93±6.91 42.77±5.12 0.01 protocol was approved by the Ethics Committee of Kunming Medical University. Informed consent was obtained from all patients. Methods. The functional results of the two groups were compared at 6 months, 1 year and 2 years after surgery, using the SF-36 survey method. Regarding the orthotopic reconstruction, most of the surgical techniques were based on Studer's method. At a time point of >6 months after surgery, the SF-36 survey was conducted by mail to determine the QOL of patients with an orthotopic and that of patients with a non-orthotopic neobladder. The SF-36 survey consisted of 36 questions and the 2nd question was a self-evaluation of health status, which was not included in the score calculation. We assessed 8 aspects of health-related QOL: physical functioning, role-physical functioning, bodily pain, general health, vitality, social functioning, role-emotional functioning and mental health. The number of questions regarding each health concept ranged from 2 for social functioning and bodily pain to 10 for physical functioning and the number of response options per question ranged from 2 (yes or no) to 6 (none, very mild, mild, moderate, severe or very severe). The score per question was estimated for each health concept, ranging from 0 to 100, with higher scores indicative of an improved outcome. For the orthotopic neobladder patients, a detailed continence questionnaire (not validated) including voiding questions was examined on the same day as the SF-36 survey. Statistical analysis. Descriptive data were reported as the means ± SD. The differences in the mean values between the ileal neobladder and the cutaneous diversion patients were analyzed by the Mann-Whitney U test. Data regarding the percentage of patients with a neobladder, the number of males, the number of patients with a pathological stage T3 or higher and the current disease status were analysed by the χ 2 test. P<0.05 was considered to indicate a statistically significant difference. Results Comparison of data from the SF-36 survey between the experimental and control groups at the time point of 6 months. Figure 1. Comparison of data from the Short-Form Health Survey (SF-36) between the experimental and control groups at 6 months ( * P<0.05). TMH, All 82 patients (100%) were available for assessment at the time point of 6 months. A total of 51 out of the 54 patients in the experimental group (94.4%) and 26 out of the 28 in the control group (92.9%) were available for assessment at the time point of 12 months. A total of 45 patients in the experimental group (83.3%) and 23 in the control group (82.1%) were available for assessment at the time point of 24 months. All questionnaires were qualified. At the time point of 6 months, the response rate was similar for the experimental group (54/54, 100%) and for the control group (28/28, 100%). The majority of patients (76/82, 92.7%) indicated that their physical condition was worse compared to 1 year before when were the questionnaires completed. Data from the SF-36 survey are provided in Table Ⅰ and Fig. 1. Comparison of data from the SF-36 survey between the experimental and control groups at the time point of 12 months. The social functioning and mental health scores in the experimental group were significantly higher compared to those in the control group (P<0.05) and the QOL score in the experimental group was higher compared to the control group; however, the difference was not statistically significant (P>0.05). At the time point

760 Table Ⅱ. Comparison of data from the Short Form Health Survey (SF-36) between the experimental and control groups at 12 months. Items Experimental group (n=51) Control group (n=26) P-value Physical functioning 23.22±4.37 22.14±2.03 0.17 Role-physical functioning 6.46±1.18 6.07±1.24 0.26 Bodily pain 10.47±2.43 10.64±3.06 0.63 General health 19.64±5.23 16.18±5.01 0.03 Vitality 17.38±3.27 15.33±5.06 0.11 Social functioning 8.72±0.96 3.47±1.04 0.01 Role-emotional functioning 4.29±1.17 3.62±0.93 0.01 Mental health 24.36±4.74 14.71±3.89 0.01 Overall health 114.7±17.32 93.17±11.24 0.11 Total physical health 55.69±6.34 48.17±5.47 0.08 Total mental health 57.49±4.93 40.16±6.36 0.01 Table Ⅲ. Comparison of data from the Short Form Health Survey (SF-36) between the experimental and control groups at 24 months. Items Experimental group (n=45) Control group (n=23) P-value Physical functioning 23.07±3.44 24.15±3.28 0.43 Role-physical functioning 5.79±0.54 5.21±1.96 0.26 Bodily pain 9.27±1.54 10.33±2.17 0.56 General health 19.63±7.26 11.35±6.20 0.01 Vitality 16.37±3.19 14.28±5.17 0.06 Social functioning 7.32±1.94 4.86±0.46 0.01 Role-emotional functioning 3.92±0.81 3.12±0.42 0.01 Mental health 23.17±3.06 15.10±2.79 0.01 Overall health 112.8±11.23 95.41±9.86 0.01 Total physical health 56.13±5.31 47.67±3.12 0.09 Total mental health 58.22±9.71 41.47±4.29 0.01 Figure 2. Comparison of data from the Short Form Health Survey (SF-36) between the experimental control groups at 12 months ( * P<0.05). TMH, Figure 3. Comparison of data from the Short Form Health Survey (SF-36) between the experimental control groups at 24 months ( * P<0.05). TMH, of 12 months, the response rates of the experimental group and the control group were 51/54 (94.4%) and 26/28 (92.9%), respectively. In the experimental group, 1 patient succumbed to multiple metastases of bladder cancer, 1 expired due to non-cancerous causes and 1 was lost to follow up. In the experimental group, 22 patients (43.1%) indicated that their physical

YANG et al: GENERAL HEALTH SURVEY ON ORTHOTOPIC URINARY DIVERSION SURGERY 761 condition was worse compared to 1 year before, 27 (52.9%) indicated that their physical condition had improved compared to 1 year before and 2 (3.9%) observed no differences compared to 1 year before when they completed the questionnaires. In the control group, 16 patients (61.5%) indicated that their physical condition was worse compared to 1 year before and 10 (38.5%) indicated that their physical condition had improved compared to 1 year before when they completed the questionnaires. Data from the SF-36 survey are provided in Table Ⅱ and Fig. 2. The general health, social functioning, role-emotional functioning and mental health scores in the experimental group were significantly higher compared to those in the control group (P<0.05). The QOL score in the experimental group was higher compared to that in the control group; however, the difference was not statistically significant (P>0.05). Comparison of data from the SF-36 survey between the experimental and control groups at the time point of 24 months. At the time point of 24 months, the response rates of the experimental and control groups were 45/54 (83.3%) and 23/28 (82.1%), respectively. In the experimental group, one patient succumbed to multiple metastases of bladder cancer and 5 patients died due to non-cancerous causes. In the control group, 2 patients succumbed to non-cancerous causes and 1 was lost to follow up. In the experimental group, 8 patients (17.8%) indicated that their physical condition was worse compared to 1 year before, 11 (24.4%) indicated that their physical condition had improved compared to 1 year before and 26 (57.8%) observed no differences compared to 1 year before when they completed the questionnaires. In the control group, 14 patients (60.9%) indicated that their physical condition was worse compared to 1 year before, 7 (30.4%) indicated that their physical condition had improved compared to 1 year before and 2 (8.7%) observed no differences compared to 1 year before when they completed the questionnaires. Data from the SF-36 survey are provided in Table Ⅲ and Fig. 3. The general health, social functioning, role-emotional functioning, mental health and QOL scores in the experimental group were significantly higher compared to those in the control group (P<0.05). Discussion Urinary reconstruction is indispensable following radical cystectomy for invasive bladder cancer (5,12). In our institute (Yunnan Institute of Urology, China), orthotopic neobladder reconstruction procedures were performed when the patients had the appropriate indications for this type of surgery from the viewpoint of cancer control, as well as when the patients requested the surgery. However, we performed non-orthotopic neobladder procedures when the patients did not have the appropriate indications for the construction of an ileal neobladder. Due to the increasing number of patients receiving an orthotopic rather than a non-orthotopic neobladder following radical cystectomy, it is significant to accurately demonstrate the health-related QOL differences between the two procedures, in order to select the patient-appropriate type of urinary diversion, considering that they exhibit similar morbidity and mortality rates. Although QOL is increasingly recognized as an important outcome measure following treatment for urological malignancy, the QOL findings after a cystectomy remain a controversial subject. The health-related QOL, as well as the micturition status and continence following a cystectomy, are important considerations in selecting the optimal treatment modality (13,14). Therefore, we investigated whether there were differences in QOL between the experimental and the control groups. Numerous questionnaires have been developed in order to evaluate the health-related QOL. The health-related QOL in patients with urinary reconstructions has been evaluated thus far using various types of questionnaires (15). The SF-36 score is extensively used worldwide and is considered to be accurate (16). Furthermore, it is a standard questionnaire that may be applied to patients as well as to healthy subjects. In addition, the questions may be easily answered within a short time and they are limited to the evaluation of basic issues regarding overall health. Our data demonstrated that more patients perceived themselves as healthy following an orthotopic urinary diversion and their total health scores were higher compared to those of patients undergoing a non-orthotopic urinary diversion; however, there were no differences in the scores of physical functioning between the two groups. There were no statistical differences in the health-related QOL between the orthotopic and the non-orthotopic neobladder group; however, the functional results of orthotopic neobladder patients were satisfactory and consistent with those reported by other studies. In conclusion, the orthotopic neobladder reconstructive surgery may be performed on patients with the appropriate indications from the viewpoint of cancer control, particularly on patients concerned over a negative body image due to the presence of a urinary stoma. Our data may assist patients in the selection of the most appropriate treatment option. However, studies including larger patient samples may help elucidate the relative psychological benefits associated with various types of urinary tract reconstruction. References 1. Hautmann RE, de Petriconi RC, Pfeiffer C and Volkmer BG: Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 61: 1039-1047, 2012. 2. Kübler H and Gschwend JE: Ileal neobladder in women with bladder cancer: cancer control and functional aspects. Curr Opin Urol 21: 478-482, 2011. 3. Erber B, Schrader M, Miller K, et al: Morbidity and quality of life in bladder cancer patients following cystectomy and urinary diversion: a single-institution comparison of ileal conduit versus orthotopic neobladder. ISRN Urol 2012: doi: 10.5402/2012/342796. 4. Hashine K, Miura N, Numata K, Shirato A, Sumiyoshi Y and Kataoka M: Health-related quality of life after bladder preservation therapy for muscle invasive bladder cancer. Int J Urol 15: 403-406, 2008. 5. Jeong IG, You D, Kim J, et al: Factors associated with nonorthotopic urinary diversion after radical cystectomy. World J Urol 30: 815-820, 2012. 6. Philip J, Manikandan R, Venugopal S, Desouza J and Javle PM: Orthotopic neobladder versus ileal conduit urinary diversion after cystectomy - a quality-of-life based comparison. Ann R Coll Surg Engl 91: 565-569, 2009. 7. Takenaka A, Hara I, Soga H, et al: Assessment of long-term quality of life in patients with orthotopic neobladder followed for more than 5 years. Int Urol Nephrol 43: 749-754, 2011. 8. Cesarino CB, Beccaria LM, Aroni MM, Rodrigues LC and Pacheco Sda S: Quality of life of patients with implantable cardioverser-defibrillator: the usage of SF-36 questionnaire. Rev Bras Cir Cardiovasc 26: 238-243, 2011.

762 9. Maurino J, Cordero L and Ballesteros J: The subjective wellbeing under neuroleptic scale - short version (SWN-K) and the SF-36 health survey as quality of life measures in patients with schizophrenia. Patient Prefer Adherence 6: 83-85, 2012. 10. McPherson A and Martin CR: A review of the measurement properties of the 36-item short-form health survey (SF-36) to determine its suitability for use in an alcohol-dependent population. J Psychiatr Ment Health Nurs: Mar 27, 2012 (Epub ahead of print). 11. Wan C, Tu X, Messing S, et al: Development and validation of the general module of the system of quality of life instruments for chronic diseases and its comparison with SF-36. J Pain Symptom Manage 42: 93-104, 2011. 12. Kang SG, Ko YH, Jang HA, et al: Initial experience of robotassisted radical cystectomy with total intracorporeal urinary diversion: comparison with extracorporeal method. J Laparoendosc Adv Surg Tech A 22: 456-462, 2012. 13. Goossens-Laan CA, Kil PJ, Ruud Bosch JL and De Vries J: Pre-diagnosis quality of life (QoL) in patients with hematuria: comparison of bladder cancer with other causes. Qual Life Res: Mar 30, 2012 (Epub ahead of print). 14. Miyanaga N, Akaza H, Shinohara N, et al: Assessment of QOL and survival for patients undergoing radical cystectomy or bladder preservation for invasive bladder cancer. Nihon Hinyokika Gakkai Zasshi 90: 445-453, 1999 (In Japanese). 15. Ridolo E, Baiardini I, Meschi T, et al: Erratum to: HRQoL questionnaire evaluation in lactose intolerant patients with adverse reactions to foods. Intern Emerg Med: Feb 24, 2012 (Epub ahead of print). 16. Velanovich V, Younga J, Bhandarkar V, et al: A single, global patient-centered measure from the SF-36 instrument to assess surgical outcomes and quality of life: a pilot study. World J Surg 36: 2045-2050, 2012.